Centessa Pharmaceuticals (NASDAQ:CNTA) is one of the best up and coming stocks with huge upside potential. On September 9, LifeSci Capital analyst Francois Brisebois reiterated a Buy rating on Centessa Pharmaceuticals and set a price target of $39.00. In Q2 2025, Centessa Pharmaceuticals reported that the company had$404.1 million in cash and investments, which is projected to fund its operations into mid-2027. The company’s R&D expenses increased to $42.7 million in Q2 2025, up from$32.8 million in Q2 ...